1163P Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial

REMINET: A European, multicentre, PHASE II/III randomized double-blind, placebo-controlled study evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps4148 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS4148-TPS4148

Author(s):

Come Lepage ◽

Laetitia Dahan ◽

Jean-Louis Legoux ◽

Karine Le Malicot ◽

Rosine Guimbaud ◽

...

Keyword(s):

Maintenance Therapy ◽

Neuroendocrine Tumours ◽

Controlled Study ◽

Line Treatment ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase ◽

Pancreatic Neuroendocrine Tumours ◽

A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study of Onartuzumab (METMAB) with Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum as First-Line Treatment for Patients (PTS) with Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Annals of Oncology ◽

10.1016/s0923-7534(20)33827-8 ◽

2012 ◽

Vol 23 ◽

pp. ix445

Author(s):

H. Wakelee ◽

W. Yu ◽

K. Rittweger ◽

V.E. Paton

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Controlled Study ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Randomized Phase Ii ◽

A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study of Onartuzumab (METMAB) in Combination with Paclitaxel + Cisplatin (or Carboplatin) as First-Line Treatment for Patients (PTS) With Stage IIIB or IV Squamous Non-Small Cell Lung Cancer (NSCLC)

Annals of Oncology ◽

10.1016/s0923-7534(20)33828-x ◽

2012 ◽

Vol 23 ◽

pp. ix445 ◽

Cited By ~ 1

Author(s):

F.R. Hirsch ◽

D. Gandara ◽

R. Govindan ◽

V.E. Paton ◽

W. Yu

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Controlled Study ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Randomized Phase Ii ◽

Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours

Digestive and Liver Disease ◽

10.1016/j.dld.2017.02.004 ◽

2017 ◽

Vol 49 (5) ◽

pp. 568-571

Author(s):

Côme Lepage ◽

Laetitia Dahan ◽

Nadia Bouarioua ◽

Christos Toumpanakis ◽

Jean-Louis Legoux ◽

...

Keyword(s):

Maintenance Therapy ◽

Neuroendocrine Tumours ◽

Line Treatment ◽

First Line ◽

Pancreatic Neuroendocrine Tumours ◽

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Case Medical Research ◽

10.31525/ct1-nct04033354 ◽

2019 ◽

Author(s):

Keyword(s):

Stage Iiib ◽

Phase Iii ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Dose Dense ◽

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

Oncology ◽

10.1159/000120626 ◽

2007 ◽

Vol 73 (1-2) ◽

pp. 9-20 ◽

Cited By ~ 11

Author(s):

Craig Underhill ◽

David Goldstein ◽

Vera A. Gorbounova ◽

Mikhail Y. Biakhov ◽

Igor S. Bazin ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First‐Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG‐1201 Study)

The Oncologist ◽

10.1634/theoncologist.2017-0640 ◽

2018 ◽

Vol 23 (8) ◽

pp. 919-927 ◽

Cited By ~ 1

Author(s):

Goro Nakayama ◽

Ayako Mitsuma ◽

Yuki Sunagawa ◽

Kiyoshi Ishigure ◽

Hiroyuki Yokoyama ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Japanese Patients ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

Annals of Oncology ◽

10.1093/annonc/mdi047 ◽

2005 ◽

Vol 16 (2) ◽

pp. 282-288 ◽

Cited By ~ 83

Author(s):

M.M. Borner ◽

J. Bernhard ◽

D. Dietrich ◽

R. Popescu ◽

M. Wernli ◽

...

Keyword(s):

Quality Of Life ◽

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(20)30934-x ◽

2020 ◽

Vol 395 (10240) ◽

pp. 1835-1844 ◽

Cited By ~ 29

Author(s):

Ralf Gutzmer ◽

Daniil Stroyakovskiy ◽

Helen Gogas ◽

Caroline Robert ◽

Karl Lewis ◽

...

Keyword(s):

Line Treatment ◽

First Line ◽

Primary Analysis ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽